

# Lysophosphatidic Acid Receptor 1 - Drugs In Development, 2021

<https://marketpublishers.com/r/LE5EA9D62DDDEN.html>

Date: July 2021

Pages: 39

Price: US\$ 3,500.00 (Single User License)

ID: LE5EA9D62DDDEN

## Abstracts

Lysophosphatidic Acid Receptor 1 - Drugs In Development, 2021

### SUMMARY

Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) pipeline Target constitutes close to 10 molecules. The latest report Lysophosphatidic Acid Receptor 1 - Drugs In Development, 2021, outlays comprehensive information on the Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Lysophosphatidic acid receptor 1 is a G protein-coupled receptor that binds the lipid signaling molecule lysophosphatidic acid (LPA). Lysophosphatidic acid (LPA) receptor belongs to a group known as EDG receptors. EDG receptors mediate diverse biologic functions, including proliferation, platelet aggregation, and smooth muscle contraction, inhibition of neuroblastoma cell differentiation, chemotaxis, and tumor cell invasion. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 5 and 2 respectively. Report covers products from therapy areas Respiratory, Gastrointestinal, Metabolic Disorders, Central Nervous System, Genito Urinary System And Sex Hormones, Immunology, Musculoskeletal Disorders and Toxicology which include indications Idiopathic Pulmonary Fibrosis, Diabetic Nephropathy, Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease), Non-Alcoholic Steatohepatitis (NASH), Pulmonary Fibrosis, Diabetic Neuropathy, Diarrhea, Fibrosis, Kidney Fibrosis, Radiation Toxicity (Radiation Sickness, Acute Radiation

Syndrome) and Systemic Sclerosis (Scleroderma).

Furthermore, this report also reviews key players involved in Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1)

The report reviews Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) targeted therapeutics and enlists all their major and minor projects

The report assesses Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) targeted therapeutics

## REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) -  
Overview

Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) -  
Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) -  
Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) -  
Companies Involved in Therapeutics Development

Bristol-Myers Squibb Co

Curadim Pharma Co Ltd

Epigen Biosciences Inc

Horizon Therapeutics Plc

Mercaptor Discoveries Inc

Novo Nordisk AS

RxBio Inc

Takeda Pharmaceutical Co Ltd

Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) -  
Drug Profiles

BMS-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMS-986278 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMS-986337 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CP-2090 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EPGN-2154 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EPGN-696 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HZN-825 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MD-055 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Rx-100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAK-615 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) -  
Dormant Products

Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) -  
Discontinued Products

Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) -  
Product Development Milestones

Featured News & Press Releases

Sep 28, 2011: RxBio Receives \$15m BARDA Contract For Development Of Rx100 To  
Protect Against Radiation

Appendix  
Methodology  
Coverage  
Secondary Research  
Primary Research  
Expert Panel Validation  
Contact Us  
Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Indication, 2021

Number of Products under Development by Companies, 2021

Products under Development by Companies, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Pipeline by Bristol-Myers Squibb Co, 2021

Pipeline by Curadim Pharma Co Ltd, 2021

Pipeline by Epigen Biosciences Inc, 2021

Pipeline by Horizon Therapeutics Plc, 2021

Pipeline by Mercaptor Discoveries Inc, 2021

Pipeline by Novo Nordisk AS, 2021

Pipeline by RxBio Inc, 2021

Pipeline by Takeda Pharmaceutical Co Ltd, 2021

Dormant Products, 2021

Dormant Products, 2021 (Contd..1)

Discontinued Products, 2021

## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Top 10 Indications, 2021

Number of Products by Mechanism of Actions, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Stage and Molecule Type, 2021



## I would like to order

Product name: Lysophosphatidic Acid Receptor 1 - Drugs In Development, 2021

Product link: <https://marketpublishers.com/r/LE5EA9D62DDDEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/LE5EA9D62DDDEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970